Tobira Therapeutics, a Manalapan, NJ-based developer of therapies to treat HIV, has named Andrew Hindman president and CEO, according to a news release. Hindman was most recently senior v.p. of development at Nodality, a San Francisco-based developer of molecular diagnostic tools. Tobira is in phase 2b testing of Cenicriviroc, a drug that targets two co-receptors—one required for HIV infection and the other for a number of metabolic and cardiovascular diseases. “With the right team, the right compound and the right strategy, Tobira is well-poised to realize Cenicriviroc’s potential to become an integral component of future once-daily HIV treatment regimens,” Hindman said in the release.